Given the limited number of in vivo studies exploring the combination of nanotechnology and AMPs against biofilm-forming bacteria, it is imperative to act swiftly and advance research in this area before it becomes too late to effectively address the escalating threat of biofilm-related infections and antimicrobial resistance. The gene discussed is ADSL; the disease is infection.